FUNDAMENTAL & CLINICAL PHARMACOLOGY is a distinguished journal dedicated to advancing the fields of pharmacology and clinical medicine. Published by WILEY, this journal serves as a pivotal platform for researchers, healthcare professionals, and students alike to disseminate innovative research findings and clinical applications. With an impressive history spanning from 1987 to 2024, it has consistently maintained its relevance in the scientific community, evidenced by its Q2 quartile ranking in both Pharmacology and Pharmacology (medical) categories for 2023. The journal's diverse publication range, which includes original research articles, reviews, and clinical studies, helps bridge the gap between fundamental research and practical application in healthcare settings. Although it does not offer open access, its rigorous peer-review process ensures that published content meets the highest scholarly standards, making it a vital resource for those aiming to stay at the forefront of pharmacological sciences.

Safety is a prestigious Open Access journal published by MDPI, based in Switzerland, dedicated to advancing research in the fields of public health, environmental safety, and occupational health. Since its inception in 2015, the journal has become a vital resource for researchers, practitioners, and policymakers, striving to foster innovative solutions to safety challenges in various sectors. With its rigorous peer-review process and a 2023 ranking in the Q2 category for Safety Research, as well as a notable presence in public health and environmental disciplines, Safety is well-respected in academic circles, holding a Scopus rank of 37/109 in Safety Research and 87/207 in Safety, Risk, Reliability, and Quality. The journal aims to disseminate high-quality research that not only reflects the latest advancements but also aids in developing practical strategies for risk management and safety improvement. Supported by an open-access model, Safety ensures that cutting-edge research is readily available to a global audience, fostering collaboration and knowledge sharing for a safer environment.

Expert Opinion on Drug Metabolism & Toxicology, published by Taylor & Francis Ltd, is a leading journal in the fields of pharmacology and toxicology, with a distinguished reputation gleaned from its Q1 rankings in both disciplines as of 2023. With an ISSN of 1742-5255 and an E-ISSN of 1744-7607, this journal aims to foster innovative discussions and critical insights into the metabolism and toxicological assessment of drugs, appealing to a wide audience of researchers, professionals, and students. The journal's commitment to maintaining high academic standards is reflected in its placement within the top quartiles of the Scopus rankings—ranked 17th in Toxicology and 73rd in Pharmacology—demonstrating its significant impact and relevance in advancing knowledge within the drug development sector. Published since 2005 and converging into 2024, it provides a platform for timely dissemination of expert opinions, systematic reviews, and original research, reinforcing its vital role in shaping the future of pharmacological sciences in an ever-evolving landscape.

Welcome to the Iranian Journal of Pharmaceutical Research, a pioneering publication in the field of pharmacology, toxicology, and pharmaceutics, published by BRIEFLAND. Established in 2002, this journal has been a crucial platform for disseminating innovative research and scholarly articles, contributing significantly to the advancement of pharmaceutical sciences in Iran and beyond. With an impressive trajectory leading towards a convergence of knowledge by 2024, it proudly holds a Q3 ranking in Pharmacology (Medical) and a Q2 ranking in the broader realm of Pharmacology, Toxicology, and Pharmaceutics for 2023. The journal's influence is underscored by its Scopus rank of #25/80 in General Pharmacology, Toxicology, and Pharmaceutics, placing it within the 69th percentile, therefore appealing to researchers, professionals, and students alike. Although the journal operates under a non-open access model, it remains dedicated to providing high-quality research articles that explore the latest advancements in pharmaceutical sciences, making it an essential resource for anyone involved in this vibrant field of study.

The European Journal of Pharmacology, a prestigious publication by Elsevier, serves as a vital resource in the field of pharmacology, offering rich insights into drug development and therapeutic applications. Since its inception in 1967, this journal has evolved to encompass groundbreaking research, including pharmacokinetics, toxicology, and innovative pharmacological methodologies, making it an essential platform for researchers and professionals alike. With an impressive impact factor that places it in the Q1 category of pharmacological journals and a Scopus ranking of #49 out of 313, the journal is recognized in the 84th percentile within its category, solidifying its significance in the academic community. Although the journal is not open access, it continues to attract contributions from leading scientists worldwide, ensuring that cutting-edge findings are disseminated effectively. The European Journal of Pharmacology not only highlights advancements in drug discovery and clinical applications but also promotes interdisciplinary collaboration, ultimately contributing to the progress of healthcare globally.

BIOLOGICAL & PHARMACEUTICAL BULLETIN, published by the PHARMACEUTICAL SOC JAPAN, is a prominent peer-reviewed journal that serves the fields of medicine, pharmaceutical science, and pharmacology. With an ISSN of 0918-6158 and an E-ISSN of 1347-5215, this publication has been crucial in disseminating innovative research since its inception in 1993, and it continues to contribute significantly to the body of knowledge as it converges towards 2024. Despite being classified as a non-open access journal, it maintains a respectable Q3 ranking in Medicine (miscellaneous) and Q2 in Pharmaceutical Science, highlighting its critical role in advancing scientific discourse in these areas. With Scopus rankings placing it in the 51st percentile for Pharmaceutical Science and 38th percentile for Pharmacology, BIOLOGICAL & PHARMACEUTICAL BULLETIN is an essential resource for researchers, professionals, and students looking to stay abreast of cutting-edge developments and trends in biomedicine and drug development.

Welcome to the JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES, a prestigious open access journal published by FRONTIERS MEDIA SA since 2008, dedicated to advancing research in the fields of pharmacy and pharmaceutical sciences. With its strong rooting in Canada, this journal has established itself within the academic community by consistently delivering high-quality studies and insights, as evidenced by its respectable Q2 ranking in both Medicine (miscellaneous) and Pharmaceutical Science categories for 2023, along with a notable 77th percentile ranking in Pharmaceutical Science on Scopus. Spanning over two decades of publication from 1998 to 2024, the journal focuses on critical research areas including pharmacology, toxicology, and drug development. By providing open access to its articles, the journal ensures that vital scientific information is readily available to researchers, professionals, and students alike, fostering collaboration and innovation within these essential disciplines. We invite you to explore the latest findings and contribute to the ongoing dialogue in pharmaceutical research through this essential platform.

PHARMAZIE is a prestigious, peer-reviewed journal published by AVOXA-MEDIENGRUPPE DEUTSCHER APOTHEKER GMBH, focusing on the dynamic field of pharmaceutical science since its inception in 1947. With its ISSN 0031-7144 and a current impact factor placing it in the Q2 category of Pharmaceutical Science journals, PHARMAZIE has established itself as a pivotal resource for researchers, practitioners, and students alike. The journal emphasizes the dissemination of high-quality, original research in pharmacology, toxicology, and pharmaceutics, contributing to the advancement of knowledge and innovation in these fields. While currently not open access, the journal maintains a commendable Scopus rank of #94 out of 183 in its category, highlighting its relevance and appeal to the academic community. With a commitment to bridging the gap between research and practical applications, PHARMAZIE plays a crucial role in shaping the future of pharmaceutical practices and policies.

Pharmacopidemiology and Drug Safety is a prestigious academic journal published by Wiley, dedicated to exploring the field of pharmacology and epidemiological studies since its inception in 1992. With its ISSN 1053-8569 and E-ISSN 1099-1557, the journal has achieved notable recognition, ranking Q2 in Epidemiology and Q1 in Medical Pharmacology in the 2023 category quartiles. Its Scopus rankings further enhance its reputation, placing it at 105th in the field of pharmacology and at 63rd in epidemiology, reflecting its commitment to publishing high-quality research that informs clinical practices and public health policies. Although it operates under a subscription model rather than open access, Pharmacopidemiology and Drug Safety plays a critical role in disseminating vital knowledge regarding drug safety and effectiveness, making it an essential resource for researchers, professionals, and students looking to stay at the forefront of advancements in the medical field.

Expert Opinion on Drug Safety is a prestigious academic journal dedicated to advancing knowledge in the fields of drug safety and pharmacology. Published by Taylor & Francis Ltd, this journal serves as an essential resource for researchers and professionals seeking to explore the complexities of drug interactions, adverse effects, and risk management. With an impressive impact factor and recognized as a Q1 journal in both the Medicine (Miscellaneous) and Pharmacology (Medical) categories, it ranks favorably at #78 out of 272 in Scopus, placing it in the 71st percentile among its peers. Operating under a rigorous peer-review process, the journal publishes original research, expert reviews, and opinion pieces that contribute to a deeper understanding of drug safety practices. While not an open access journal, it remains a vital platform for disseminating pivotal findings and fostering scholarly dialogue, ensuring that critical insights reach a global audience. With continuous publication from 2002 to 2024, Expert Opinion on Drug Safety is a key reference for anyone involved in pharmaceutical research, healthcare practice, or drug regulation.